# Clinical Utility of Prenatal Whole Exome Sequencing

Study · id `cardio:ct-nct03482141` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03482141](<https://clinicaltrials.gov/study/NCT03482141>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03482141

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 316 participants.

## Technical summary

Registry record NCT03482141. Allocation not applicable; no masking; primary purpose diagnostic. Start 2017-08-01 (actual); primary completion 2022-05-13 (actual). Results posted on 2023-04-14.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 316 participants (enrolled count; ClinicalTrials.gov record NCT03482141, source copy `cardio:ctgov-nct03482141-2023-04-14`, retrieved 2026-10-26)
- Started: 2017-08-01 (actual) (ClinicalTrials.gov record NCT03482141, source copy `cardio:ctgov-nct03482141-2023-04-14`, retrieved 2026-10-26)
- Primary completion: 2022-05-13 (actual) (ClinicalTrials.gov record NCT03482141, source copy `cardio:ctgov-nct03482141-2023-04-14`, retrieved 2026-10-26)
- Completion: 2022-05-13 (actual) (ClinicalTrials.gov record NCT03482141, source copy `cardio:ctgov-nct03482141-2023-04-14`, retrieved 2026-10-26)
- Results first posted: 2023-04-14 (ClinicalTrials.gov record NCT03482141, source copy `cardio:ctgov-nct03482141-2023-04-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03482141, source copy `cardio:ctgov-nct03482141-2023-04-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03482141-2023-04-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Utility of Prenatal Whole Exome Sequencing
- Acronym: PWES
- Condition: Structural Anomalies
- Condition: Cardiac Anomalies
- Condition: Central Nervous System Anomalies
- Condition: Thorax Anomalies
- Condition: Genito-urinary Anomalies
- Condition: Gastrointestinal Anomalies
- Condition: Skeletal Anomalies
- Condition: Multiple Anomalies
- Intervention (Device): Whole Exome Sequencing (WES)
- Lead sponsor: University of California, San Francisco
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: University of California, San Francisco (`cardio:org-university-of-california-san-francisco`)

## Provenance

Content hash: 54db6b4bfb0c8108f896cb99e5adbb62160536361e58e9c43092b4cc82eb941c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
